CD8A and neoplasm: Though screening the epigenetic compounds library, researchers identified that suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor that has been approved for the treatment of cutaneous T-cell lymphoma [175], facilitates SOX2 acetylation and proteasome-dependent degradation, therefore abolishing the SOX2-mediated resistance of tumor cells to CD8+T cells [145].